Drug Search Results
More Filters [+]

house dust mites

Alternative Names: house dust mites
Latest Update: 2024-07-18
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Nondrug

Route of Administration: Sublingual,Injection,Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Canada | Czech | Denmark | Finland | Germany | Greece | Hungary | Iceland | Ireland | Israel | Korea | Luxembourg | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Sweden | Switzerland | Turkey | Ukraine | United States

Approved Indications: None

Known Adverse Events: None

Company: Probelte Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for house dust mites

Countries in Clinic: Spain

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Asthma, Allergic|Dust mite Hypersensitivity|Environmental Hypersensitivity|Rhinitis, Allergic

Phase 2: Conjunctivitis, Allergic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PROACAROS

P3

Recruiting

Environmental Hypersensitivity|Dust mite Hypersensitivity

2026-06-01

2018-003427-11

P3

Active, not recruiting

Asthma, Allergic|Rhinitis, Allergic

2023-10-07

TiME (short allergen immunotherapy mites)

P2

Completed

Asthma, Allergic|Conjunctivitis, Allergic|Rhinitis, Allergic

2023-02-04

Recent News Events